- Home
- AXL vs ATXS Comparison
AXL vs ATXS Comparison
Compare AXL & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- ATXS
- Stock Information
- Founded
- AXL 1994
- ATXS 2008
- Country
- AXL United States
- ATXS United States
- Employees
- AXL N/A
- ATXS N/A
- Industry
- AXL Auto Parts:O.E.M.
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- AXL Consumer Discretionary
- ATXS Health Care
- Exchange
- AXL Nasdaq
- ATXS Nasdaq
- Market Cap
- AXL 487.5M
- ATXS 401.2M
- IPO Year
- AXL 1999
- ATXS 2015
- Fundamental
- Price
- AXL $3.41
- ATXS $4.66
- Analyst Decision
- AXL Hold
- ATXS Strong Buy
- Analyst Count
- AXL 7
- ATXS 5
- Target Price
- AXL $6.93
- ATXS $26.60
- AVG Volume (30 Days)
- AXL 2.5M
- ATXS 298.7K
- Earning Date
- AXL 05-02-2025
- ATXS 05-08-2025
- Dividend Yield
- AXL N/A
- ATXS N/A
- EPS Growth
- AXL N/A
- ATXS N/A
- EPS
- AXL 0.29
- ATXS N/A
- Revenue
- AXL $6,124,900,000.00
- ATXS N/A
- Revenue This Year
- AXL N/A
- ATXS N/A
- Revenue Next Year
- AXL N/A
- ATXS N/A
- P/E Ratio
- AXL $11.85
- ATXS N/A
- Revenue Growth
- AXL 0.75
- ATXS N/A
- 52 Week Low
- AXL $3.17
- ATXS $4.62
- 52 Week High
- AXL $7.98
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- AXL 19.69
- ATXS 24.34
- Support Level
- AXL $4.38
- ATXS $5.24
- Resistance Level
- AXL $4.63
- ATXS $5.60
- Average True Range (ATR)
- AXL 0.20
- ATXS 0.33
- MACD
- AXL -0.08
- ATXS -0.12
- Stochastic Oscillator
- AXL 15.89
- ATXS 1.73
Stock Price Comparison Chart: AXL vs ATXS
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.